-
Actelion Pharmaceuticals Ltd. is a
pharmaceuticals and
biotechnology company established in
December 1997,
headquartered in
Allschwil near Basel, Switzerland...
-
orexin receptors,
which was
being developed by the
pharmaceutical companies Actelion and GSK for the
treatment of insomnia.
Development of the drug was abandoned...
-
After Actelion was
bought by
Johnson &
Johnson in 2017,
Idorsia was spun out into a new
company and
started operating on the same
campus where Actelion was...
-
approved for
medical use in the
European Union in June 2023. In July 2004,
Actelion started a
clinical trial of
miglustat to
treat Tay–Sachs disease, particularly...
-
acquired Actelion in a $30 billion deal, the
largest ever
purchase by the company.
After the purchase,
Johnson &
Johnson spun off
Actelion's research...
-
brand name Opsumit, is an
endothelin receptor antagonist developed by
Actelion and
approved for the
treatment of
pulmonary arterial hypertension (PAH)...
-
Abbott –
Abbott Laboratories Inc.
Accord –
Accord Healthcare Ltd.
Actelion –
Actelion Pharmaceuticals UK Ltd
Aesica pharmaceuticals -
Aesica Queenborough...
- and is
marketed by
Bayer Schering Pharma AG in the
European Union and by
Actelion Pharmaceuticals in the US. In the US,
iloprost is
indicated for the treatment...
-
Specialty Chemicals, Clariant, Hoffmann-La Roche,
Basilea Pharmaceutica, and
Actelion are
headquartered there.
Pharmaceuticals and
specialty chemicals have become...
- Selexipag, sold
under the
brand name Uptravi, is a
medication developed by
Actelion for the
treatment of
pulmonary arterial hypertension (PAH).
Selexipag and...
